AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05945810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLL-018 immediate-release tablet
Description: 20mg TLL-018 immediate-release tablet BID
Study NCT05949099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat 150 mg by mouth twice-daily continuously for Cycles 1 through 3. Treatment with nirogacestat may continue via this study protocol for up to 24 months (26 cycles of treatment), unless there is progression of disease, intolerance, start of new anticancer therapy, or Subject Study Completion or Termination occurs.
Study NCT05949099 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoablation procedure (single session) of one tumor mass between Cycles 3 and 4 of nirogacestat treatment
Study NCT06554392 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample
Description: Blood sample from each subject to detect Glutathione Peroxidase 4.
Study NCT06584799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hesperidin+Diosmin combination 1000
Description: A venotonic agent that also has angioprotective properties. It reduces venous distensibility and blood stasis, reduces capillary permeability and increases their resistance.~Hesperidin+Diosmin combination 1000 dosing regimen is 1000 mg once daily for 2 months
Study NCT06507956 — intervention group
Intervention type: OTHER
Intervention: Characterize the physical activity and sedentary lifestyle profile of adults with cystic fibrosis
Description: Eligible patients will be presented with the study during a routine care visit CF center, at the end of a physiotherapy, adapted physical activity or nurse session, in accordance with the schedule for the day's visit, with no changes induced by this study. After sufficient time for reflection, patients agreeing to participate will be given self-questionnaires. From this visit, a proposal to participate at V2 will be made only to the inactive/hight sedentary patients on the ONAPS-PAQ questionnaire, under elexacaftor-tezacaftor-ivacaftor (ETI). Volunteers will know their participation in either actimetry or a qualitative interview following a draw. At V2, 40 patients will be offered a 7-day longitudinal follow-up by actimetry, and between 10 to 15 patients will take part in an qualitative semi-structured interview identifying motivational barriers and levers for action. At V3, patients monitored by actimetry will be invited to return their actimeter by postage-paid mail.
Study NCT05920694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Positive Airway Pressure Device (CPAP)
Description: Metabolic studies will be performed before and after initiation of CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
Study NCT05920694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Continuous Positive Airway Pressure Device (CPAP)
Description: Metabolic studies will be performed before and after the study period of 12 weeks. After 12 weeks, participants will immediate receive CPAP therapy, which is currently the first-line standard of care for treatment of patients with OSA, both with and without hypoxia.
Study NCT06253884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RespirAct
Description: RespirAct device-based computer-controlled gas delivery at different concentrations as per protocol
Study NCT06292234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSI
Description: Fabrication of PSI implants using virtual surgical planning
Study NCT06292234 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional miniplates
Description: Ready made miniplates
Study NCT05054049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interventional Diagnostic Device Arm
Description: Point of care testing venous blood diagnostic device.
Study NCT05054049 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Usual care provided to patient without use of point of care testing device
Study NCT05050981 — intervention group
Intervention type: DRUG
Intervention: Hormone replacement therapy
Description: Hormone replacement therapy: menopause hormone therapy with estrogen-only or oestrogen-progestin.
Study NCT05050981 — intervention group
Intervention type: DRUG
Intervention: Selective serotonin reuptake inhibitors
Description: Selective serotonin reuptake inhibitors: anyone in the category, e.g.: fluoxetine, sertraline, etc.
Study NCT05922488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: Umbilical cord milking : uncut umbilical cord and squeeze it from the placenta several times toward the infant usually within 20 seconds.
Study NCT05922488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: delayed cord clamping: delivery the delivering obstetrician will wait at least 60 s before clamping the umbilical cord
Study NCT05806931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102, oxaliplatin, irinotecan with bevacizumab
Description: Participants will be treated with the study drugs until radiological evidence of disease progression or until treatment discontinuation secondary to adverse events. TAS-OX alternating with TAS-IRI (sequential TASOXIRI) with Bevacizumab, in the treatment of mCRC.
Study NCT05787067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Belief Model-Based Mobile Online Training
Description: Health Belief Model-Based Mobile Online Training
Study NCT06480604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Participants in this arm will receive a daily dose of 2x10\^9 Colony Forming Units (CFU) of a multi strain probiotic (live bacterium), corresponding to 2 capsules once daily, for 6 months.
Study NCT06480604 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in this arm will receive an equivalent placebo for the duration of the study (6 months).
Study NCT04945512 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural Analgesia
Description: In the anesthesia preparation room, an epidutal catheter will be placed with a toue needle through the L4-5 spinal space. After induction of general anesthesia, 10 ml of 0.25% bupivacaine will be injected through the epidural catheter.Afterwards, peroperative and postoperative analgesia will be provided with epidural PCA.
Study NCT05893355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acupressure group
Description: Application to Acupressure Group~* Participants in this group will be interviewed for the first time at postpartum week 1, and for the second time between 4-6 weeks postpartum. The application will be explained and a voluntary consent form will be signed.~* Participant Information Form will be filled in by the researcher by face-to-face interview.~* The VAS, which will be applied to the puerperant women for the first time in the first week of the postpartum week and for the second time between the 4th-6th weeks, will be filled by the participant just before the application to evaluate the back pain.~* The VAS Evaluating Back Pain after the application will be filled in by the participant.~* The participant will be informed that the study has been completed.
Study NCT05047068 — intervention group
Intervention type: DEVICE
Intervention: OCS Heart System
Description: The TransMedics® OCS Heart System is a portable system available for ex-vivo maintenance of a donor heart in a metabolically active and beating state.~The OCS Heart System's innovative technology was designed to comprehensively overcome the historical limitations of cold storage. The OCS Heart System expands the utilization of donor hearts by enabling the use of donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of cold static cardioplegic preservation.
Study NCT05869760 — intervention group
Intervention type: OTHER
Intervention: Carotenoid Intake
Description: Carotenoid intake calculated from food diary records reported by guardians.
Study NCT05869760 — intervention group
Intervention type: OTHER
Intervention: Serum carotenoid concentrations
Description: Serum carotenoid concentrations measured by HPLC.
Study NCT05933616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Sokru device
Description: Different induced glycaemic states in people living with diabetes (PwD).
Study NCT06160245 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise therapy
Description: core stabilization exercises
Study NCT06160245 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Description: core stabilization exercises
Study NCT06040255 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone, prednisolone, prednisone
Description: Any generic or brand-name methylprednisolone at the appropriate dose may be used. Likewise, any generic or brand-name prednisolone, or prednisone, at the appropriate dose may be used.
Study NCT05205863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cofact
Description: Human prothrombin complex concentrate
Study NCT05205863 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cofact
Description: Human prothrombin complex concentrate
Study NCT04847687 — intervention group
Intervention type: DRUG
Intervention: methylprednisolone
Description: Patients who are hospitalized with a pre-diagnosis of severe COVID-19 pneumonia and who are started on methylprednisolone will be divided into two groups according to the drug dose. Groups will be compared in terms of length of hospital stay, intensive care needs and prognosis.
Study NCT06496724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel/neutrophil drug
Description: Isolate the patients' autologous neutriphil cells, induce and culture them with albumin paclitaxel in vitro. The final product for Albumin paclitaxel/neutrophil drug.
Study NCT05882370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Patients were treated with TIPS plus Cadonilimab (10mg/kg, intravenously, d1, Q3W) to a maximum total cycle of 18 unless any evidence of disease progression or unacceptable side effects.
Study NCT05882370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transjugular intrahepatic portosystemic shunt (TIPS)
Description: transjugular intrahepatic portosystemic shunt (TIPS)
Study NCT06000332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InogenOne Rove 6 Portable Oxygen Concentrator
Description: overnight use of Portable Oxygen Concentrator, 6 hours minimum
Study NCT05668975 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training
Description: A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
Study NCT05668975 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: A mechanical pressure threshold loading device (POWERbreathe, POWERbreathe International Ltd, UK) will be used for the training.
Study NCT04993950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sustained natural apophyseal glides
Description: SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
Study NCT06144892 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proactive Therapy
Description: Uses AI to make predictions and preventions of future apneic events.
Study NCT06539182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily oral dose of DZD8586 at 25 mg.
Study NCT06539182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily oral dose of DZD8586 at 50 mg.
Study NCT06539182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DZD8586
Description: Daily oral dose of DZD8586 at 75 mg.
Study NCT04993950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sustained natural apophyseal glides
Description: SNAGS will be applied in flexion, extension and rotation for a few seconds with 3 repetitions on the first day and 10 repetitions from the next visit.
Study NCT04993950 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAGS with thoracic postural correction techniques
Description: thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
Study NCT04993950 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SNAGS with thoracic postural correction techniques
Description: thoracic extension in sitting, Wall angle stretch and Corner stretch, while the therapist-facilitated stretches will be seated mid-thoracic stretch and prone mid thoracic stretch. Stretches will be maintained for 15-20 seconds with 10 repetitions of each stretch per session
Study NCT05320458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: 1-Pulmonary Rehabilitation: Pulmonary rehabilitation program was applied at 40-60% of submaximal heart rate, 3 days a week for a total of 8 weeks. Diaphragmatic breathing, pursed lip breathing and segmental breathing exercises were practiced with the patients in the company of a physiotherapist. Walking and aerobic exercise training was given.
Study NCT04702555 — intervention group
Intervention type: DRUG
Intervention: VTS-K
Description: An oral combination drug of VTS-Aspirin and ketamine (VTS-K)
Study NCT04398719 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: [11C]PBR28
Description: The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan
Study NCT04744155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Level Intervention
Description: Behavioral intervention that assesses uptake of contraception and seeks follow-up care.
Study NCT04744155 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Behavioral intervention that assesses uptake of contraception from follow-up care.
Study NCT05967871 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Participants will receive approximately 50 grams of human stool/150mL (approximately 107 microbes/mL of suspension) in saline, prepared as per standard collection, preparation, and screening protocols for FMT infusion developed by our institutional stool bank in accordance with recognized standards. Fecal microbiota transplant infused via existing enteral feeding tube or upper elective endoscopy (with infusion into the duodenum) x1.
Study NCT05308823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent
Description: The patients in this group will receive traditional treatment of IIH for 3 months in addition to venus sinus stent
Study NCT05763849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure Treatment (IE)
Description: Interoceptive Exposure Therapy (IE) targets food avoidance in Anorexia Nervosa. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Early sessions include using exposure to foods and counterconditioning to pair a positive stimulus with a food that would typically produce food avoidance. Parents are trained to model this at home. Sessions mid-way through address the use of non-judgmental description of appearance during mirror exposure. Sessions at the end of the 20 weeks are focused on recognizing change, planning for future obstacles, and developing a relapse prevention plan to continue practicing distress tolerance, counter-conditioning, and food/body exposure.
Study NCT05763849 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Based Treatment (FBT)
Description: Family-Based Therapy (FBT) includes parent-enforced contingencies to increase value of eating and decrease the value of food avoidance. Each session the therapist weighs the patient, checks-in, and reviews weekly homework. Sessions occur weekly for 20 weeks, with the first session lasting 1.5 hours and the remaining sessions one hour. Sessions consist of checking in with the patient, discussion of the week's implementation of refeeding, and helping parents separate the illness from their child. In session 2, a family meal provides the therapist with an opportunity for direct observation of the familial interaction patterns around eating. The therapist makes careful and persistent requests for united parental action toward re-feeding and/or regulating eating habits, the primary concern at this point of the treatment, and the therapist tries to create and reinforce a strong parental alliance around efforts at feeding the child.
Study NCT04398719 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: [11C]PBR28
Description: The radiotracer, \[11C\]PBR28, will be administered at the beginning of each PET scan
Study NCT04398719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose lipopolysaccharide
Description: Subjects will receive intravenous lipopolysaccharide.
Study NCT04398719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-dose lipopolysaccharide
Description: Subjects will receive intravenous lipopolysaccharide.
Study NCT04398719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intradermal Capsaicin
Description: A small dose of capsaicin will be administered by intradermal injection.
Study NCT04398719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intradermal Capsaicin
Description: A small dose of capsaicin will be administered by intradermal injection.
Study NCT05064722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self Forming Magnets (SFM)
Description: To create the duodenal-ileal diversion, the duodenal magnet will be placed transorally in the proximal duodenum and the distal magnet will be placed in the ileum. Magnets are coupled and a compression induced anastomosis is created.
Study NCT05894694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: first-line scheme+compound kushen injection
Description: FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab+compound kushen injection Compound Kushen injection: intravenous infusion, 20ml at a time, diluted with 200ml sodium chloride injection, once a day, each cycle of chemotherapy should reach the cumulative dose of 200ml.
Study NCT05894694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: palliative care group first-line scheme
Description: FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab
Study NCT04943848 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rHSC-DIPGVax
Description: Off-the-shelf, neoantigen heat shock protein vaccine
Study NCT05201859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).
Study NCT04943848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: BALSTILIMAB is a human monoclonal antibody that targets programmed cell death 1 (PD1)
Study NCT04943848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zalifrelimab
Description: ZALIFRELIMAB is a human monoclonal immunoglobulin G1k subclass (IgG1k) antibody that specifically recognizes cytotoxic T lymphocyte-associated protein 4 (CTLA-4, also known as CD152)
Study NCT05116709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT6005 injection
Description: Six dose groups were set up, including 10mg (initial dose) group, 30mg group, 100mg group, 300mg group, 600mg group and 900mg group, respectively.
Study NCT06402162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The study will include 40 tennis players diagnosed with rotator cuff lesions who meet the inclusion criteria. The 1st group will be randomly divided into 2 groups as control (n=20) and 2nd group as core exercise (n=20). Unlike the control group, core exercises will be added to the routine exercise program of tennis players once a day, 3 days a week for 8 weeks.
Study NCT06581237 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eat2Win App
Description: Voluntary use of the app will occur throughout the sport season.
Study NCT04952571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab and Bevacizumab
Description: Stage 1: Targeted therapy induction phase: bevacizumab 5mg/kg, intravenous infusion, once every two weeks, 2 cycles in total.~Phase 2: Targeted combined immunotherapy: once every three weeks with the following drugs: (1) bevacizumab 7.5mg/kg intravenously;(2) Carrelizumab: 200mg/ time, intravenous infusion.
Study NCT06638788 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knee extension
Description: Participants will perform 20, 40, and 60% of thier 1 rep maximum (1RM) at 18, 12, and 6 reps respectively.
Study NCT06642792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK129
Description: Subjects receive AK129 intravenously.
Study NCT06642792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK117
Description: Subjects receive AK117 intravenously.
Study NCT06639529 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tests of the expression of CXCL3 in various tissues
Description: 1.The expression of CXCL3 in peripheral blood PBMC was detected by RT-qPCR. 2.The levels of CXCL3 in serum and urine were detected by Elisa method. 3.Clinical data collection includes the patient \&#39;s name, gender, weight, height, biochemical indicators, urine test indicators, renal biopsy data, etc. 4.The expression of CXCL3 in renal tissue was determined by immunohistochemistry.